Philogen SpA
78Q
Company Profile
Business description
Philogen SpA is a biotechnology company. The company develops biotech products for the imaging and therapy of life-threatening diseases. The company's focus is predominantly related to oncology drug development, although the company has also brought products for the treatment of chronic inflammatory diseases to the clinic. Its pipeline products include Nidlegy; Fibromun; Darleukin; Dodekin; Dekavil and others. Geographically, the company operates in the European Union, Switzerland, and the United States of America.
Contact
Piazza La Lizza No. 7
Siena53100
ITAT: +39 0577206941
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
201
Stocks News & Analysis
stocks
Magellan merger modestly dilutive
Our view on how shareholders should respond to the Magellan merger.
stocks
ASX listed gold miner under pressure due to lower production
Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks
3 ASX opportunities after earnings season
Uncovering key opportunities following February’s results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,847.70 | 14.20 | 0.16% |
| CAC 40 | 8,058.24 | 83.75 | 1.05% |
| DAX 40 | 23,932.75 | 201.83 | 0.85% |
| Dow JONES (US) | 46,993.26 | 46.85 | 0.10% |
| FTSE 100 | 10,433.41 | 29.81 | 0.29% |
| HKSE | 26,025.42 | 156.88 | 0.61% |
| NASDAQ | 22,479.53 | 105.35 | 0.47% |
| Nikkei 225 | 55,239.40 | 1,539.01 | 2.87% |
| NZX 50 Index | 13,315.60 | 133.37 | 1.01% |
| S&P 500 | 6,716.09 | 16.71 | 0.25% |
| S&P/ASX 200 | 8,640.60 | 14.40 | 0.17% |
| SSE Composite Index | 4,062.98 | 13.08 | 0.32% |